Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?

Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group.

AIDS Rev. 2017 Sep 19;19(3). [Epub ahead of print]

PMID:
28926559
2.

HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells.

Cesana D, Santoni de Sio FR, Rudilosso L, Gallina P, Calabria A, Beretta S, Merelli I, Bruzzesi E, Passerini L, Nozza S, Vicenzi E, Poli G, Gregori S, Tambussi G, Montini E.

Nat Commun. 2017 Sep 8;8(1):498. doi: 10.1038/s41467-017-00609-1.

3.

Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis.

Fugazzola P, Coccolini F, Montori G, Ceresoli M, Baggi P, Costanzo A, Tomasoni M, Gregis F, Nozza S, Ansaloni L.

J Gastrointest Oncol. 2017 Jun;8(3):572-582. doi: 10.21037/jgo.2017.03.11.

4.

PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection.

Di Biagio A, Riccardi N, Signori A, Maserati R, Nozza S, Gori A, Bonora S, Borderi M, Ripamonti D, Rossi MC, Orofino G, Quirino T, Nunnari G, Celesia BM, Martini S, Sagnelli C, Mazzola G, Colletti P, Bartolozzi D, Bini T, Ladisa N, Castelnuovo F, Saracino A, Lo Caputo S.

PLoS One. 2017 Jul 20;12(7):e0181433. doi: 10.1371/journal.pone.0181433. eCollection 2017.

5.

Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient.

Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group.

J Acquir Immune Defic Syndr. 2017 Jul 8. doi: 10.1097/QAI.0000000000001496. [Epub ahead of print]

PMID:
28708810
6.

Obstetric risk factors for poor neonatal adaptation at birth.

Crovetto F, Fumagalli M, De Carli A, Baffero GM, Nozza S, Dessimone F, Vergani P, Fedele L, Mosca F, Acaia B.

J Matern Fetal Neonatal Med. 2017 Jul 11:1-7. doi: 10.1080/14767058.2017.1344635. [Epub ahead of print]

PMID:
28629245
7.

Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study.

Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPO Study Group.

J Antimicrob Chemother. 2017 Jun 10. doi: 10.1093/jac/dkx169. [Epub ahead of print]

PMID:
28605493
8.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2017 Apr;40(2):86-98.

9.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
10.

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.

Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, Rovelli C, Lazzarin A, Castagna A, Tambussi G.

J Antimicrob Chemother. 2017 May 1;72(5):1549-1550. doi: 10.1093/jac/dkx073. No abstract available.

PMID:
28333303
11.

Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control.

Malnati MS, Ugolotti E, Monti MC, Battista D, Vanni I, Bordo D, Sironi F, Larghero P, Marco ED, Biswas P, Poli G, Vicenzi E, Riva A, Tarkowski M, Tambussi G, Nozza S, Tripodi G, Marras F, De Maria A, Pistorio A, Biassoni R.

Sci Rep. 2017 Feb 13;7:42470. doi: 10.1038/srep42470.

12.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group.

Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9.

PMID:
27956268
13.

Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.

Ripa M, Pogliaghi M, Chiappetta S, Nozza S, Soria A, Coppalini G, Rovelli C, Tambussi G.

J Clin Virol. 2016 Dec;85:86-89. doi: 10.1016/j.jcv.2016.10.016. Epub 2016 Oct 31.

PMID:
27865174
14.

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.

Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, Rovelli C, Lazzarin A, Castagna A, Tambussi G.

J Antimicrob Chemother. 2017 Feb;72(2):632-633. doi: 10.1093/jac/dkw439. Epub 2016 Oct 17. No abstract available.

PMID:
27798217
15.

48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.

Nozza S, Pignataro AR, Galli L, Svicher V, Alteri C, Boeri E, Ripa M, Castagna A, Sampaolo M, Clementi M, Perno CF, Lazzarin A.

New Microbiol. 2016 Jul;39(3):192-196.

16.

Dysfunctions in the migratory phenotype and properties of circulating immature transitional B cells during HIV-1 infection.

Amu S, Fievez V, Nozza S, Lopalco L, Chiodi F.

AIDS. 2016 Sep 10;30(14):2169-77. doi: 10.1097/QAD.0000000000001182.

PMID:
27281060
17.

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.

Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.

18.

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group.

J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.

PMID:
26945711
19.

Early diagnosis and retention in care of HIV-infected patients through rapid salivary testing: a test-and-treat fast track pilot study.

Parisi MR, Soldini L, Negri S, Vidoni GM, Gianotti N, Nozza S, Schlusnus K, Dorigatti F, Lazzarin A.

New Microbiol. 2016 Jan;39(1):57-60.

20.

Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART.

Chiappetta S, Ripa M, Galli L, Razzari C, Longo V, Galli A, Faioni EM, Nozza S, Lazzarin A, Tambussi G.

J Antimicrob Chemother. 2016 Jun;71(6):1627-31. doi: 10.1093/jac/dkw010. Epub 2016 Feb 16.

PMID:
26888911

Supplemental Content

Loading ...
Support Center